HUE054075T2 - CD40 elleni nem fukozilált antitestek adagolása és bevitele - Google Patents

CD40 elleni nem fukozilált antitestek adagolása és bevitele

Info

Publication number
HUE054075T2
HUE054075T2 HUE15854895A HUE15854895A HUE054075T2 HU E054075 T2 HUE054075 T2 HU E054075T2 HU E15854895 A HUE15854895 A HU E15854895A HU E15854895 A HUE15854895 A HU E15854895A HU E054075 T2 HUE054075 T2 HU E054075T2
Authority
HU
Hungary
Prior art keywords
antibodies
dosage
administration
fucosylated anti
fucosylated
Prior art date
Application number
HUE15854895A
Other languages
English (en)
Inventor
Shyra Gardai
Che-Leung Law
Stanford Peng
Jing Yang
Haley Neff-Laford
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054075(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of HUE054075T2 publication Critical patent/HUE054075T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0009—Making of catheters or other medical or surgical tubes
    • A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/002—Packages specially adapted therefor ; catheter kit packages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HUE15854895A 2014-10-29 2015-10-29 CD40 elleni nem fukozilált antitestek adagolása és bevitele HUE054075T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072031P 2014-10-29 2014-10-29
US201562134955P 2015-03-18 2015-03-18

Publications (1)

Publication Number Publication Date
HUE054075T2 true HUE054075T2 (hu) 2021-08-30

Family

ID=55858352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15854895A HUE054075T2 (hu) 2014-10-29 2015-10-29 CD40 elleni nem fukozilált antitestek adagolása és bevitele

Country Status (22)

Country Link
US (8) US11213584B2 (hu)
EP (2) EP3212230B1 (hu)
JP (5) JP6691113B2 (hu)
KR (2) KR20170072884A (hu)
CN (2) CN107073118B (hu)
AU (2) AU2015339128C1 (hu)
BR (1) BR112017008959A2 (hu)
CA (1) CA2963720C (hu)
CY (1) CY1124033T1 (hu)
DK (1) DK3212230T3 (hu)
EA (1) EA036498B1 (hu)
ES (1) ES2864756T3 (hu)
HK (1) HK1243328A1 (hu)
HU (1) HUE054075T2 (hu)
IL (2) IL299075A (hu)
MX (1) MX2017005152A (hu)
PL (1) PL3212230T3 (hu)
PT (1) PT3212230T (hu)
SG (2) SG10201913099YA (hu)
SI (1) SI3212230T1 (hu)
WO (1) WO2016069919A1 (hu)
ZA (2) ZA201702347B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913099YA (en) * 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
US20210001032A1 (en) * 2015-03-27 2021-01-07 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
IL260732B1 (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
HUE056670T2 (hu) 2016-05-27 2022-02-28 Abbvie Biotherapeutics Inc Anti-CD40 antitestek és alkalmazásaik
WO2018088850A2 (ko) 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
BR112020018761A2 (pt) * 2018-03-13 2020-12-29 Hibercell, Inc. Imunoterapia combinada com beta-glucano e agonista de cd40
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
KR20210095891A (ko) 2018-11-23 2021-08-03 스트라이크 파마 아베 이중 특이적 접합체
FR3089597B1 (fr) 2018-12-06 2020-11-20 Gaztransport Et Technigaz Cuve étanche et thermiquement isolante
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
WO2020190834A1 (en) * 2019-03-18 2020-09-24 Score Pharma, Inc. Compounds for inhibiting fucosylation and methods for using the same
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022536982A (ja) * 2019-06-21 2022-08-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 癌およびその他の疾患の処置のためのα３β１インテグリンの標的化
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022251311A1 (en) 2021-05-25 2022-12-01 Seagen Inc. Methods of quantifying anti-cd40 antibodies
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
AU1072701A (en) 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
BR0110190A (pt) 2000-04-19 2003-12-30 Tanox Inc Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
EP1717251B1 (en) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Therapy for B-cell malignancies using human anti-CD40 antibodies
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
PL1885399T3 (pl) * 2005-05-26 2011-04-29 Seattle Genetics Inc Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
BRPI0619586A2 (pt) * 2005-12-09 2018-08-28 Seattle Genetics Inc método para o tratamento ou prevenção de um distúrbio associado com cd40
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CA2704499C (en) 2007-11-07 2020-03-10 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
US8551485B2 (en) 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
SG10201913099YA (en) * 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies

Also Published As

Publication number Publication date
EP3212230A1 (en) 2017-09-06
PT3212230T (pt) 2021-04-19
CY1124033T1 (el) 2022-05-27
IL251552B1 (en) 2023-01-01
MX2017005152A (es) 2017-08-04
EA036498B1 (ru) 2020-11-17
SI3212230T1 (sl) 2021-08-31
CN107073118B (zh) 2022-03-01
AU2015339128A1 (en) 2017-04-20
SG10201913099YA (en) 2020-02-27
US20230201343A1 (en) 2023-06-29
JP6833080B2 (ja) 2021-02-24
AU2015339128C1 (en) 2021-12-16
KR20240073140A (ko) 2024-05-24
IL299075A (en) 2023-02-01
JP2017533909A (ja) 2017-11-16
EA201790932A1 (ru) 2017-08-31
US20240075135A1 (en) 2024-03-07
JP2020050677A (ja) 2020-04-02
CA2963720A1 (en) 2016-05-06
AU2021202407A1 (en) 2021-05-20
US11202827B2 (en) 2021-12-21
IL251552A0 (en) 2017-05-29
CN114522228A (zh) 2022-05-24
DK3212230T3 (da) 2021-04-19
US20170333556A1 (en) 2017-11-23
WO2016069919A1 (en) 2016-05-06
US11213584B2 (en) 2022-01-04
US20220249662A1 (en) 2022-08-11
EP3212230B1 (en) 2021-01-20
ES2864756T3 (es) 2021-10-14
CA2963720C (en) 2024-05-14
US20170137528A1 (en) 2017-05-18
AU2015339128B2 (en) 2021-01-21
EP3212230A4 (en) 2018-06-20
CN107073118A (zh) 2017-08-18
EP3831847A1 (en) 2021-06-09
HK1243328A1 (zh) 2018-07-13
SG11201702598XA (en) 2017-05-30
IL251552B2 (en) 2023-05-01
JP6691113B2 (ja) 2020-04-28
KR20170072884A (ko) 2017-06-27
PL3212230T3 (pl) 2021-07-26
US20220265822A1 (en) 2022-08-25
JP2023126406A (ja) 2023-09-07
JP2021088609A (ja) 2021-06-10
US20230201344A1 (en) 2023-06-29
ZA202102219B (en) 2022-10-26
ZA201702347B (en) 2021-07-28
US20240075134A1 (en) 2024-03-07
JP2020200343A (ja) 2020-12-17
BR112017008959A2 (pt) 2018-01-16
JP7165166B2 (ja) 2022-11-02

Similar Documents

Publication Publication Date Title
ZA202102219B (en) Dosage and administration of non-fucosylated anti-cd40 antibodies
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
IL259713A (en) Anti-dr5 antibodies and methods of using them
ZA201606630B (en) Anti-ox40 antibodies and methods of use
GB201701039D0 (en) Vertically integrated continuous delivery of an application
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
PT3191167T (pt) Válvula para administração de fluidos farmacêuticos
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
GB201419540D0 (en) Delivery of drugs
HK1223630A1 (zh) 抗- 療法的實施與用量
ZA201701492B (en) Pyrazolothiazole compound and medicine
HRP20181406T1 (hr) Farmaceutski dozni oblici
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201415486D0 (en) Infusion package and method of manufature
GB201409644D0 (en) Inhalers and dosing devices for inhalers
GB201409272D0 (en) Synergistic combination of analgesic drugs